Valuation: Structure Therapeutics Inc.

Market Cap 3.59B 3.11B 2.9B 2.67B 5.03B 341B 5.09B 34.07B 13.37B 171B 13.49B 13.19B 566B P/E 2026 *
-35.3x
P/E 2027 * -24.3x
Enterprise Value 2.59B 2.24B 2.09B 1.92B 3.63B 246B 3.67B 24.54B 9.63B 123B 9.71B 9.5B 408B EV / Sales 2026 *
67.3x
EV / Sales 2027 * 69,563x
Free-Float
76.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week+6.72%
Current month+5.18%
1 month-5.46%
3 months+22.94%
6 months-30.98%
Current year-27.35%
1 week 46.58
Extreme 46.575
51.66
1 month 44.8
Extreme 44.8001
57.07
Current year 35.78
Extreme 35.78
94.77
1 year 15.85
Extreme 15.85
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 30/04/2022
Chief Executive Officer 62 30/04/2019
Chief Operating Officer 49 14/04/2026
Director TitleAgeSince
Director/Board Member 62 31/01/2019
Chairman 68 18/01/2022
Director/Board Member 66 28/03/2022
Date Insider Type Main position Quantity % Market Cap.
22/07/26
F-Prime Inc.
OtherCompany 17,452 0.0101%
22/07/26
F-Prime Inc.
OtherCompany 0 0%
14/07/26 Fiscal year

Chief Technology Officer

86,658 0.0620%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%+6.72%+202.94%+72.75% 3.59B
+4.35%+16.60%+58.11%+95.21% 64.9B
+1.98%+2.25%+31.03%+72.68% 54.05B
+0.91%-0.83%-17.01%-13.43% 23.16B
+0.27%-3.98%-11.28%+350.30% 21.46B
+1.87%+9.47%+30.87%-5.63% 21.25B
+0.99%+3.36%+38.42%-24.99% 17.94B
+9.88%+23.61%+222.87%+385.49% 17.03B
+3.29%+5.61%+21.01%+636.23% 14.99B
+1.25%+2.48%+51.36%+179.72% 14.25B
Average +2.66%+5.20%+62.83%+174.83% 25.26B
Weighted average by Cap. +2.83%+5.91%+46.43%+141.19%

Financials

2026 *2027 *
Net sales 38.46M 33.31M 31.05M 28.56M 53.92M 3.66B 54.52M 365M 143M 1.83B 144M 141M 6.06B 41.67K 36.09K 33.64K 30.94K 58.41K 3.96M 59.07K 395K 155K 1.98M 157K 153K 6.57M
Net income -288M -249M -232M -214M -403M -27.35B -408M -2.73B -1.07B -13.68B -1.08B -1.06B -45.31B -423M -366M -342M -314M -593M -40.24B -600M -4.01B -1.58B -20.13B -1.59B -1.55B -66.68B
Net Debt -1B -870M -811M -746M -1.41B -95.55B -1.42B -9.53B -3.74B -47.81B -3.77B -3.69B -158B -693M -600M -559M -514M -971M -65.87B -982M -6.57B -2.58B -32.96B -2.6B -2.54B -109B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
233
Date Price Change Volume
05/08/26 US$50.53 +1.79% 713,610
04/08/26 US$49.64 +2.65% 876,827
03/08/26 US$48.36 +0.67% 326,381
31/07/26 US$48.04 -2.89% 407,588
30/07/26 US$49.47 +4.48% 384,071
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
50.53USD
Average target price
104.83USD
Spread / Average Target
+107.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock